Podcasts about Teva

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

"Come as you are works in Japan when leaders are also willing to read the air and meet people where they are". "Japan isn't as risk-averse as people think; it is uncertainty avoidance and consensus norms like nemawashi and ringi-sho that slow decisions". "In Japan, numbers are universal, but how people feel about those numbers is where real leadership begins". "For foreign leaders, kindness, patience, and genuine curiosity are far more powerful than charisma or title". "Women leaders who embrace their own style, instead of copying male role models, can quietly transform Japanese workplaces".   Joanne Lin is Senior Director, APAC, for Deckers Brands, the American company behind UGG, HOKA, and Teva. Born in Taiwan and raised in Canada, she later completed her MBA at Boston University and began her career in Boston, working in a trading company and then at Merrill Lynch Investment Company. In 2000, she moved to Japan for family reasons and has since built a 25-year leadership career in this complex market. In Japan, Joanne first held senior finance roles, including Head of Finance for Reebok Japan and CFO for Aegis Media, where she worked on mergers and acquisitions. She joined Deckers over thirteen years ago as CFO for Japan and was later asked to step in as interim Country Manager for Deckers Japan. Today she is back in an APAC-wide role, responsible for finance and strategy across 15 markets, including Japan, China, South Korea, Hong Kong, Australia and New Zealand. Her remit covers subsidiaries and distributor markets alike, requiring constant adaptation across cultures. Throughout her journey, Joanne has learned to reconcile a direct, North American style with Japan's more implicit, consensus-driven culture. Often mistaken for Japanese because of her appearance, she calls herself the "invisible gaijin", using that ambiguity to observe carefully, read body language, and bridge cultural expectations. Her leadership story is one of resilience, curiosity, and the quiet confidence to lead as herself in a country that often expects conformity. Joanne Lin's leadership journey began far from Japan. Born in Taiwan and raised in Toronto, she grew up immersed in North American directness, meritocracy, and straight-talking feedback. After completing an MBA at Boston University, she started her career in Boston, first at a trading company and then at Merrill Lynch Investment Company, building a strong foundation in finance. Numbers, ratios, and cash flows were her native business language long before she ever heard the phrase kūki o yomu — "reading the air" — in Japan. In 2000, she moved to Japan for family reasons, expecting to build a career but not realising how deeply the culture would challenge her assumptions about leadership. She entered the corporate world here without Japanese language skills and without local experience. Physically, many colleagues assumed she was Japanese, or at least of Japanese descent, and treated her accordingly. She jokes that she became an "invisible gaijin": expected to understand unspoken rules despite never having grown up with them. Early on, she discovered that in Japan, silence often speaks louder than words. Concepts akin to nemawashi — the quiet groundwork of building consensus before meetings — and the unspoken pressure to align with the group meant that decisions rarely came from a single, charismatic leader. Instead, she had to watch faces, posture and micro-reactions around the table. While she came from an environment where people said "yes" or "no" clearly, in Japan phrases like "I'll think about it" could mean "no" 80% of the time. Learning to interpret these signals became as important as reading the P&L. Her career advanced steadily through senior finance roles: Head of Finance for Reebok Japan, CFO for Aegis Media leading M&A, and later CFO for Deckers Japan. Over thirteen years at Deckers, she helped steer the growth of brands such as UGG and the fast-rising performance brand HOKA in one of the world's most competitive footwear markets. Eventually, she was asked to serve as interim Country Manager for Deckers Japan, an opportunity that tested her ability to go beyond numbers and lead entire functions including sales, marketing, HR and retail. Joanne's leadership philosophy is grounded in being genuine and transparent. She believes in explaining the "why" behind decisions, giving context, and aligning people rather than simply seeking agreement. She spends time helping non-finance colleagues understand what gross margin, discounts and operating income mean in practical terms, translating finance into everyday language rather than using it as a gatekeeping tool. Engagement surveys, where Japan often scores modestly compared with global benchmarks, have been a recurring theme in her work. Rather than blaming culture, she looks at how questions are worded, how norms shape responses, and then uses those insights to design practical remedies — from "lunch and learn" sessions to cross-functional gatherings and new-joiner lunches with senior leaders. As a woman leader, Joanne has wrestled with impostor syndrome yet chosen to step forward anyway. She sees many high-potential women in Japan holding back, waiting to be "perfect" before raising their hand. Her message to them is clear: trust yourself, recognise your natural strengths in communication and empathy, and accept that no leader — male or female — is ever fully ready. In the end, her story is about blending global experience with local nuance, leading with kindness and clarity, and proving that one can honour Japanese culture while still bringing a distinct, authentic leadership style to the table. Q&A Summary What makes leadership in Japan unique? For Joanne, leadership in Japan is defined by what is not said. The real meeting often happens before and after the official meeting, through nemawashi, where stakeholders quietly shape outcomes. In the room, kūki o yomu — reading the air — is critical: leaders must observe body language, side glances and subtle hesitations to interpret what people truly think. Formal tools like ringi-sho workflows, built on stamped approvals and consensus, reinforce a collective approach to decision-making. Japanese employees often assume the leader should already know their needs without them having to say it. That expectation of intuitive understanding, combined with a strong norm of harmony, makes empathetic listening and patience indispensable leadership skills. Why do global executives struggle? Global executives often arrive with a Western template: clear targets, rapid decisions, direct feedback. In Japan, that can clash with a culture that prizes stability, seniority and group consensus. Leaders may misinterpret indirect communication as indecisiveness or lack of ambition, when in fact people are carefully weighing the impact on the group. Engagement surveys then show Japan at the bottom of global rankings, and headquarters misreads this as disengagement, rather than a reflection of conservative scoring norms. Many foreign leaders also underestimate how much time must be invested in trust-building, one-on-one conversations, and slow-burn relationship work before people feel safe to share ideas or challenge the status quo. Is Japan truly risk-averse? Joanne sees Japan as more uncertainty-avoidant than risk-averse in the pure financial sense. As a finance professional, she knows that commercial risk can be quantified — through scenarios, ratios and forecasts. But in Japan, the social and reputational risks loom equally large: who will be blamed if this fails, what will it do to group harmony, how will customers react? These uncertainty factors slow decisions more than the numbers themselves. Leaders who introduce tools like decision intelligence platforms, scenario simulation or even digital twins of supply chains can help Japanese teams see risk in a structured way, reducing the emotional fear around uncertainty and making experimentation feel safer. What leadership style actually works? The style that works for Joanne is grounded in transparency, modesty and consistency. She leads by example, explaining not only what must be done, but why, and what it means for individuals and teams. She tries to give her people "airtime", resisting the urge — common to many finance leaders — to jump straight to the solution. In practice, that means listening to ideas without immediate judgement, thanking people publicly for their input, and celebrating small wins as much as big milestones. She maintains high standards but increasingly recognises that not everyone should be held to the same work rhythm she sets for herself. Alignment, not forced agreement, is the goal: people may disagree but still commit to the path once they feel heard. How can technology help? Technology, in Joanne's world, is not just about efficiency; it is a bridge between data and human behaviour. Advanced analytics, dashboards and decision-support tools can make trade-offs between margin, volume and investment more tangible for non-finance teams. AI-driven text analysis of engagement comments can surface themes that traditional surveys miss, helping leaders understand sentiment behind Japan's modest scoring patterns. Scenario modelling and digital twins of operations can turn abstract risks into concrete options, making it easier for consensus-driven teams to move forward. At its best, technology supports nemawashi by giving everyone a shared, data-informed picture, rather than replacing dialogue. Does language proficiency matter? Joanne arrived in Japan with no Japanese language ability and was forced to become an intense observer of body language and context. That experience convinced her that leadership is possible without fluency — but far more sustainable with it. Learning Japanese shows respect, reduces distance, and makes informal conversations and humour possible. Even basic proficiency helps leaders understand nuance in ringi documents, hallway chats, and customer feedback. She encourages foreign leaders to invest in language learning not as a checkbox, but as a signal of commitment to the market and to their teams. What's the ultimate leadership lesson? Her core lesson is simple yet demanding: be kind, be open, and be yourself. Leaders should stop expecting perfection from themselves and from others, especially in a country where external shocks like currency swings, tariffs and pandemics can derail even the best-laid plans. Instead, they should focus on doing their best, communicating clearly, and treating people with respect. For women leaders especially, Joanne's message is to step forward even when self-doubt whispers otherwise — to recognise that their strengths in empathy, communication and cultural sensitivity are not "soft" add-ons but central to effective leadership in Japan. In the long run, success here is less about heroics and more about steady, human-centred leadership that people genuinely want to follow. Timecoded Summary [00:00] The conversation opens with an introduction to Deckers Brands, the American company headquartered in Santa Barbara and best known in Japan for UGG, HOKA and Teva. Joanne explains that Deckers historically functions as a holding-style company, acquiring and growing footwear brands, and that Japan is a key market where three major brands are active. She outlines her current role as Senior Director, APAC, overseeing finance and strategy across 15 countries, including both subsidiaries and distributor markets. [05:20] Joanne traces her career arc: Taiwanese by birth, raised in Canada, MBA from Boston University, then finance roles in Boston with a trading company and Merrill Lynch Investment Company. In 2000 she relocates to Japan for family reasons, later becoming Head of Finance for Reebok Japan and CFO for Aegis Media, working on M&A. She joins Deckers over thirteen years ago as CFO for Japan and eventually steps into an interim Country Manager role, before returning to a wider APAC mandate based in Japan. [12:45] The discussion shifts to cultural adjustment. Because she "looks Japanese", colleagues initially assume she understands Japanese norms. She describes becoming an "invisible gaijin", held to local expectations without having grown up here. She learns to read the air, focusing on facial expressions, body language and context. Phrases like "I'll consider it" often conceal a "no", and she gradually becomes adept at interpreting such indirect communication. Her direct North American instincts must be tempered by Japanese expectations for restraint and harmony. [19:30] Finance and human reactions to numbers come into focus. Joanne notes that while sales, gross margin and SG&A appear objective, different functions interpret them in varied ways: finance may celebrate high margins while sales may worry they are under-investing. She stresses the importance of explaining financial concepts in simple terms, almost as if speaking to a 10-year-old, so that everyone can understand consequences. Her temporary shift from CFO to GM broadens her empathy for non-finance views and deepens her appreciation for cross-functional tension. [26:10] Attention turns to team engagement and communication. Japan's engagement survey scores routinely trail global averages, a pattern she attributes partly to cultural modesty and translation issues. Instead of accepting low scores as fate, she focuses on post-survey action: leaders are asked to talk openly with teams, understand expectations, and co-create remedies. Concrete initiatives such as "lunch and learn" sessions and new-joiner lunches with directors help break silos, humanise leadership and create informal nemawashi-like spaces where people can ask questions and share concerns. [33:40] Joanne discusses culture-building under the umbrella of Deckers' "Come as you are" value. She supports self-expression — even store staff in gender-fluid fashion — as long as it's tasteful and customer-appropriate. Her own leadership style is to be genuine, transparent and open about vulnerabilities. She balances the efficiency of top-down directives with the long-term benefits of participation: while consensus-building and alignment take time, they reduce turnover, re-training costs and disengagement. [40:15] Gender and leadership come into sharper focus. Joanne recounts her own bouts of impostor syndrome and the temptation, earlier in her career, to doubt her readiness for bigger roles. She notes that many women hesitate to raise their hands until they feel almost 100% qualified, while men may step up with far less. She encourages aspiring women leaders to recognise their strengths in empathy and nuanced communication, to "give it a try" even when not fully confident, and to view setbacks as learning rather than final verdicts. [47:30] The interview closes with advice for foreign leaders coming to Japan. Joanne emphasises being open, respectful and kind — to oneself and to others. She urges leaders to accept that Japan's deep-rooted culture will not change in a short posting, and that success depends on adapting rather than trying to remodel the country. Learning Japanese, even imperfectly, is both a sign of respect and a practical tool for building trust. Ultimately, she argues, effective leadership in Japan is about balancing data and humanity, global standards and local nuance, ambition and empathy. Author Credentials Dr. Greg Story, Ph.D. in Japanese Decision-Making, is President of Dale Carnegie Tokyo Training and Adjunct Professor at Griffith University. He is a two-time winner of the Dale Carnegie "One Carnegie Award" (2018, 2021) and recipient of the Griffith University Business School Outstanding Alumnus Award (2012). As a Dale Carnegie Master Trainer, Greg is certified to deliver globally across all leadership, communication, sales, and presentation programs, including Leadership Training for Results. He has written several books, including three best-sellers — Japan Business Mastery, Japan Sales Mastery, and Japan Presentations Mastery — along with Japan Leadership Mastery and How to Stop Wasting Money on Training. His works have also been translated into Japanese, including Za Eigyō (ザ営業), Purezen no Tatsujin (プレゼンの達人), Torēningu de Okane o Muda ni Suru no wa Yamemashō (トレーニングでお金を無駄にするのはやめましょう), and Gendaiban "Hito o Ugokasu" Rīdā (現代版「人を動かす」リーダー). In addition to his books, Greg publishes daily blogs on LinkedIn, Facebook, and Twitter, offering practical insights on leadership, communication, and Japanese business culture. He is also the host of six weekly podcasts, including The Leadership Japan Series, The Sales Japan Series, The Presentations Japan Series, Japan Business Mastery, and Japan's Top Business Interviews. On YouTube, he produces three weekly shows — The Cutting Edge Japan Business Show, Japan Business Mastery, and Japan's Top Business Interviews — which have become leading resources for executives seeking strategies for success in Japan.

What happens when you stop waiting for permission and start chasing wild, audacious goals? That's exactly what we unpack in this powerhouse episode with Mike Wardian—elite endurance athlete, record-setting runner, and all-around inspiration. From running across the United States to setting a fastest known time (FKT) on the Appalachian Trail for his age group, Mike shares the mindset behind tackling the unimaginable. But this conversation goes beyond races and records. Mike opens up about what fuels his drive, how he builds resilience through repetition, and how he balances his career, family, and love for adventure. Whether you're prepping for your first 10K or dreaming of rowing solo across the Atlantic (yep, that's on his calendar too), there's something here for everyone chasing big goals.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several groundbreaking advancements and strategic shifts in the industry that promise to reshape the landscape of patient care and therapeutic innovations.The U.S. Food and Drug Administration has introduced a novel regulatory pathway aimed at expediting the approval process for custom gene-editing therapies. Articulated by FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., this new approach is set to revolutionize personalized medicine, particularly for genetic disorders where tailored interventions are crucial. Gene editing technologies, like CRISPR-Cas9, have opened unprecedented avenues for addressing genetic conditions directly at their source. However, the regulatory framework has struggled to keep pace with these advances, often hampering innovation with lengthy and complex approval processes.This proposed pathway seeks to streamline these requirements by adopting a risk-based assessment model that considers the unique properties of gene-editing therapies. Unlike traditional drugs, which follow a uniform clinical trial path, gene-editing treatments require a more nuanced regulatory approach due to their precision and potential off-target effects. The framework emphasizes adaptive trial designs—allowing for modifications based on interim results—and integrates real-world data to create a dynamic regulatory process. This not only promises faster development times but also fosters innovation by making it easier for companies to bring cutting-edge therapies to market.The implications are far-reaching. For researchers and biotech firms, this represents a chance to reduce time-to-market significantly while maintaining high safety standards. It also sets a precedent for future regulatory models that prioritize patient-centric approaches, acknowledging the diverse genetic landscapes of individuals with rare diseases. On a broader scale, this shift underscores the increasing recognition of personalized medicine's potential to transform healthcare delivery.In parallel developments, Gilead Sciences has achieved positive phase 3 results for its single-tablet regimen combining bictegravir and lenacapavir for HIV treatment. This milestone offers hope for simplifying treatment protocols for patients currently on multi-tablet regimens, potentially enhancing adherence and improving health outcomes. Gilead's preparation for regulatory filings marks an essential step forward in their therapeutic portfolio.Turning to cancer treatment advancements, Kyowa Kirin's collaboration with Kura Oncology has led to FDA approval for an oral medication targeting a subset of acute myeloid leukemia patients. This approval highlights the power of strategic partnerships in expediting the development of targeted cancer therapies and brings new hope to patients with limited treatment options.Meanwhile, several pharmaceutical companies, including Fresenius, Sun Pharma, and Teva, have been involved in product recalls ranging from hospital drugs to antibiotics and ADHD medications. These recalls underscore ongoing challenges in maintaining drug safety standards and emphasize the need for rigorous quality control measures across the industry.Zealand Pharma has opted to pause development of its dual GLP-1/GLP-2 agonist, dapiglutide, due to an increasingly crowded metabolic disorder treatment landscape. By reallocating resources towards programs with greater clinical differentiation potential, Zealand reflects broader industry trends prioritizing investments in areas with clearer paths to market success.In malaria treatment advances, Novartis has achieved significant progress with its next-generation drug 'Ganlum,Support the show

podcast recorded with enacast.com

Shares of generics drugmaker Teva Pharma jumping double digits after earnings. Its CEO breaks down the impact of tariffs and price negotiations on margins. Then an inside look at Aramco's AI strategy, live from its headquarters in Saudi Arabia. Plus, the Supreme Court hears challenges against the Trump administration's tariff policies. A live report from outside the court room. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets multiple pathways simultaneously, potentially revolutionizing treatments for autoimmune diseases. Boehringer's commitment to these cutting-edge modalities highlights their strategy to leverage novel technologies for more effective therapeutic solutions.Similarly, Celltrion has entered a $744 million collaboration with Kaigene, focusing on two preclinical autoimmune drugs. This partnership marks Celltrion's strategic shift from biosimilars to novel biologics, positioning the company at the forefront of biologic therapeutics. By investing in early-stage research, Celltrion aims to introduce transformative therapies for autoimmune conditions, showcasing the industry's willingness to bet on groundbreaking scientific advancements.In gene editing, Azalea Therapeutics is gaining attention with its focus on permanent genome editing using a dual-vector approach. Backed by $82 million in funding and support from CRISPR pioneer Jennifer Doudna, Azalea is poised to develop potentially curative solutions through single-dose treatments. The credibility lent by a Nobel laureate adds anticipation to their research outcomes, with the potential to significantly impact gene therapy.Shifting focus to clinical trials, Sarepta Therapeutics faces challenges after missing the primary endpoint in its confirmatory trial for Duchenne muscular dystrophy drugs. Despite this setback, Sarepta is pursuing full FDA approval, emphasizing the complex interplay between clinical data and regulatory strategies. This situation underscores the critical importance of robust confirmatory trials in securing drug approvals and ensuring patient access to new therapies.Merck is making strategic moves in oncology by regaining full control over an early-phase asset and securing $700 million from Blackstone for its oncology pipeline. This dual focus on asset acquisition and financial fortification reflects Merck's aggressive growth strategy aimed at expanding its cancer treatment offerings.Emerging from stealth mode, Neok Bio has secured a $75 million investment to advance bispecific antibody-drug conjugates into clinical trials. These bispecific ADCs represent the forefront of targeted cancer therapies, aiming for precision targeting of cancer cells while minimizing off-target effects. Neok Bio's progress could significantly enhance oncology treatment paradigms through improved therapeutic indices.Turning to regulatory landscapes, Teva's recall of over half-a-million bottles of prazosin hydrochloride due to potential carcinogenic impurities highlights ongoing challenges in ensuring drug safety and quality control within manufacturing processes. Such recalls underscore the critical importance of maintaining high standards in pharmaceutical production.In broader industry developments, we see dynamic trends where scientific innovation meets strategic business decisions and regulatory considerations. The potential impact on patient care is profound, with breakthroughs in autoimmune treatments, gene editing technologies, and targeted cancer therapies poised to alter therapeutic landscapes significantly.UCB has achieved another milestone with FDA approval for Kygevvi, an ultra-rare disease medication marking their third approval in rare conditions within three years. This success underscores UCB's strategic focus on niche markets that offer less competition but significant patient impact. Advancements in genetic research aSupport the show

L'alumne de l'Escola d'Hostaleria del Coll i Rodés ha participat recentment a la semifinal del concurs Transgourment al Fòrum Gastronòmic de Barcelona.

Fes la Teva Feina del 30/10/2025 - T7 - E16 -FxN C2-E3 - El Paciente A podcast recorded with enacast.com

Com transformar la teva habitació amb el que ja tens i sense gastar molts diners? podcast recorded with enacast.com

Diuen que qui t

podcast recorded with enacast.com

In this episode of SCW for Pharma host Evren Ozkaya welcomes Katja Lumbar Globocnik, Head of U.S. Supply Chain at Exeltis and Xiromed, subsidiaries of Insud Pharma. Katja brings decades of experience across global pharmaceutical supply chains, from her early days in Europe with companies like Novartis and Sandoz to leading countless generic product launches at Teva in the United States.Evren and Katja open their discussion by comparing the dynamics of large versus small-to-mid-sized pharma companies. Katja explains how larger organizations, while rich in structure and learning opportunities, can be slowed by bureaucracy. In contrast, smaller companies operate with greater agility, allowing individuals to take broader ownership of decisions and execution. This leaner environment, she notes, cultivates problem solvers.The conversation then turns to digitalization and system maturity. Contrary to expectations, Katja argues that size doesn't guarantee sophistication. Many large companies still rely on traditional operations, while smaller firms like Insud Pharma have adopted advanced technologies, including AI-driven analytics and automation. These tools, she explains, are transforming supply chains by accelerating decision-making, enabling real-time visibility, and automating repetitive tasks.Evren and Katja also examine the management of operational excellence in multi-site environments. Katja sees clear value in driving OpEx globally, while acknowledging the growing trend toward regionalization. Together, they emphasize the importance of balancing standardization with local flexibility—especially as cloud-based systems make real-time benchmarking and performance tracking across sites possible.When discussing product launches, Katja highlights the excitement and challenges of bringing generic medicines to market. Success, she says, depends on teamwork, scenario planning, and calm risk assessment—particularly in the U.S., where speed to market is critical.Finally, the discussion circles back to digital transformation at manufacturing sites. Katja identifies alignment, investment constraints, and resistance to transparency as common barriers. Still, she believes progress is inevitable, led by plant leaders who take a holistic view, embrace visibility, and see weaknesses as opportunities for improvement.Evren closes by asking Katja what advice she would give her younger self. Her answer is simple and powerful: “Be fearless. Learn as much as you can. Go for it until someone stops you.”

Când echipa mi-a spus că ar fi potrivit ca primul episod după o pauză de 5 luni să fie despre... pauză, am strâmbat din nas. Mi s-a părut prea simplu. De ce i-ar păsa cuiva? a fost primul gând.Apoi mi-am dat seama că Thinking Made Visible a fost mereu despre gândire făcută vizibilă. Despre oameni care creează, greșesc și învață pe parcurs. Despre procesele din spatele ideilor pe care oamenii le scot în lume. Mi s-a părut firesc ca primul episod de după tăcerea asta să fie despre ce s-a întâmplat în tot acest timp: decizii și contexte, oboseală, claritate și schimbări. Uneori nu e greșită strategia, ci momentul în care o aplici. Iar pauza poate fi o parte din procesul de creștere.Am ales să nu public episoade o perioadă pentru că, la final de 2024, lumea era plină de zgomot și neliniște. Am simțit că nu e momentul potrivit să adaug încă o voce și am preferat să aștept momentul în care conversațiile noastre pot fi din nou auzite, nu doar consumate. Mi-am dat voie să observ, să analizez sistemul pe care l-am folosit, să văd ce funcționează și ce nu. A fost o perioadă de așezare şi reconfigurare a proceselor și a modului în care vreau să merg mai departe.A fost nevoie să accept greșelile făcute în ultimii ani, să decid ce păstrez și la ce renunț, să aduc oameni noi în echipă și să am curajul să reorganizez sistemul pe care nu-l mai revizuisem din 2021. Procesul a fost intens, dar necesar, pentru că orice proiect care vrea să crească are nevoie, din când în când, de o pauză conștientă.Dacă ai un business, un proiect personal sau un vis la care lucrezi de ceva timp, cred că te vei regăsi în conversația asta. Poate chiar o să vezi altfel ideea de pauză - nu ca pe o oprire, ci ca pe un moment de claritate. Vei înțelege de ce e important să-ți placă din nou procesul și cum oboseala poate fi un semn că e timpul să rearanjezi lucrurile, nu să renunți la ele.Ce înseamnă să îți reconstruiești direcția fără să pierzi esența?Cum poți transforma o etapă plină de oboseală într-o oportunitate de creștere?Cât de important e să-ți amintești, din când în când, că bucuria e cea care dă sens oricărui proiect?Mi-a fost dor de conversațiile care te fac să te gândești la tine, nu doar la ce ai de făcut.Dacă alegi să asculți Episodul 156 până la final, cred că o să-ți prindă bine. Intro (00:00)Despre conceptul Thinking Made Visible (00:25)Pauza a început, de fapt, în Decembrie 2024 (03:05)Primul sfat pentru tine (05:17)Războaie, conflicte, AI, negocieri geopolitice - toate au contribuit (06:47)Al doilea sfat pentru tine (09:13)Mă bucuram de rezultate, dar nu de proces (10:00)Al treilea sfat pentru tine (12:37)Nu am mai publicat episoade noi, dar am avut altă strategie (14:48)Cum s-au modificat cifrele din Social Media (15:24)Al patrulea sfat pentru tine (20:55)Un concept pornit din mine, creat pentru tine (22:38)

Fes la Teva Feina del 16/10/2025 - T7 - E14 -FxN C2-E1 - Mangosta - El Diluvio Universal podcast recorded with enacast.com

While many celebrate the bombing of boats in the Caribbean, that may or may not be affiliated with drug trafficking, others condemn it for political reasons.  What both arguments failed to realize is that major banking institutions across the United States, and across the world, are the biggest drug money laundering institutions. What is happening in the Caribbean is more akin to smoke and mirrors. From Chinese cartels to Mexican cartels, banks in Europe in the United States, launder much of the money. For Iran-Contra alone, we learned that the US government will illegally moves drugs, guns, and humans across borders for purposes that circumvent Congress. Threats of using the US military in Venezuela strike of decades of regime change operations in that part of the world for natural resources and to the benefit of multinational corporations. Venezuela has virtually nothing to do with the fentanyl drug trade, and very little to do even with the cocaine drug trade. Mexico is the central source of fentanyl distribution, largely from China, and yet Venezuela is the target of the US military. Companies like Teva pharmaceuticals, located in Israel, should be at the forefront of these discussions, too, considering that it is one of the primary contributors to the opioid crisis in the United States. But we leave the banks that launder the money out of the equation, just as we leave pharmaceutical companies that contribute to drug problems out of the equation, just as we neglect to address cultural issues that contribute to drug disease plagugin our country. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKWEBSITEBuyMe-CoffeePaypal: rdgable1991@gmail.comCashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

This was a straightforward Monday crossword, as Monday crosswords tend to be, and an enjoyable crossword, as all NYTimes crosswords edited by Will Shortz are destined to be. We were glad to spot the HIDEYHOLE at 33D; marvel at ICEDANCERS not too far removed at 28D; and delight at 40A, "Sure is", YEP (which, coincidentally, is our answer to the question, was this a great crossword?).We also have our JAMCOTWA™️ (Jean And Mike Crossword Of The Week Award) pronouncement, and some awesome listener mail, leading to an equally awesome discussion of a Lone Ranger catch phrase.Show note imagery: TEVA, for all your hiking sandal needsShow note links: What exactly is the Lone Ranger saying at the start of each episode, anyway?We love feedback! Send us a text...Contact Info:We love listener mail! Drop us a line, crosswordpodcast@icloud.com.Also, we're on FaceBook, so feel free to drop by there and strike up a conversation!

Vivim envoltats d'amulets i falses seguretats que mai responen. Habacuc ens recorda que només Déu és viu i té poder sobre la tempesta. Quan tot tremola, en qui confies: en la fusta muda o en el Déu que salva? És temps de posar la fe en Jesús, l'únic que dona vida i esperança.Ciutat Nova és una església per a la ciutat de Barcelona i una comunitat de persones normals i imperfectes que volem aprendre a viure segons la voluntat de Déu. Si vols saber més sobre la nostra església i ministeri: http://bcn.ciutatnova.cat/visitaTardor 2025Predicador: Dani P.

podcast recorded with enacast.com

A tecnologia e a informação têm o poder de transformar a realidade de quem convive com doenças raras, ampliando diagnósticos, promovendo conscientização e impulsionando políticas públicas mais inclusivas.No dia 27 de setembro, celebrado como o Dia Nacional da Doença de Huntington, essa reflexão ganha ainda mais relevância. A condição, que é hereditária e neurodegenerativa, impõe desafios que vão além dos sintomas: estigma, diagnóstico tardio, desigualdade no acesso ao cuidado e sobrecarga familiar e emocional.Neste episódio do podcast Moving Matters, em parceria com a Teva, Camila Pepe conversa com Gladys Miranda, presidente da Associação Brasil Huntington, e Antoine Daher, presidente da Casa Hunter.Eles discutem como a informação e a mobilização social podem transformar o cuidado em doenças raras e destacam a importância de datas celebrativas na construção de um futuro mais inclusivo.

El verdadero diseño del Arca de Noé te sorprenderá | T7 - E11 - Mangosta Descubre la verdadera forma del arca de Noé según antiguos dibujos. Exploramos los misterios de la biblia y la historia detrás de esta famosa arca. ¡Aprende sobre los animales y el plan de dios! podcast recorded with enacast.com

Fes la Teva Feina del 18/9/2025 - T7 - E10 - Mangosta - El Paralelo 37 norte podcast recorded with enacast.com

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

podcast recorded with enacast.com

Sab

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo Nordisk's drug Wegovy has successfully reduced cardiovascular risk by 57% compared to tirzepatide. Eli Lilly has terminated two mid-stage trials for a second obesity asset, while Vertex Pharmaceuticals and Enlaza Therapeutics have formed a potential $2 billion partnership to develop drugs for autoimmune diseases. Biogen and Eisai have received FDA approval for the subcutaneous maintenance formulation of Leqvembi. Arrowhead Pharmaceuticals has secured a commitment of up to $2 billion from Novartis for an siRNA Parkinson's program. The FDA's new radiopharma guidance is expected to accelerate the space, and Teva has launched the first generic version of Novo Nordisk's obesity drug Saxenda. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies focusing on innovation and new partnerships to drive progress.The FDA has issued new radiopharma guidance, which former FDA Commissioner Stephen Hahn believes is crucial for cancer therapy. Despite recent investments in radiopharmaceutical therapeutics by big pharma, the FDA's approval of updated COVID-19 vaccines with restrictions contradicts the medical freedom promised by health secretary Robert F. Kennedy Jr. Rare diseases secured four FDA firsts in August, including a win for Novo Nordisk's glp-1 drug WeGovy. Investment in new ALS therapies signals progress after setbacks, with new biotechs and collaborative initiatives showing promise at Bio2025. Other news includes the closure of Appia, Senate summons of Kennedy, updates on COVID-19 vaccines, and Lilly's obesity pill heading to the FDA. Thank you for listening to Pharma and Biotech daily.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Health Secretary Robert F. Kennedy Jr. is set to testify before the Senate Finance Committee on September 4. This comes after the removal of CDC Director Susan Monarez and the appointment of HHS Deputy Secretary Jim O'Neill as her interim replacement. Kennedy, along with FDA Commissioner Marty Makary and CBER Director Vinay Prasad, had previously been vocal against vaccine mandates during the COVID-19 pandemic, citing concerns about limiting medical choice. However, the FDA, under their leadership, has now approved updated COVID-19 vaccines with restrictions that go against this stance.RFK's vaccine restrictions are being viewed as restricting promised medical freedom. The FDA recently gave the green light to updated COVID-19 shots from Pfizer, Moderna, and Novavax but with certain limitations. This news comes as Teva introduces the first GLP-1 generic for obesity to the market, and J&J discontinues its rheumatoid arthritis program after disappointing mid-stage data. Kennedy's upcoming testimony highlights the ongoing turmoil within CDC leadership and raises questions about the conflicting messages surrounding vaccine mandates and medical freedom.

How did a couple of California surfers turn a flip-flop side hustle into one of the best-performing stocks of the past 20 years? In this two-part special, Skippy & Doogles unpack the wild origin story of Deckers Outdoor—makers of Teva, UGG, Hoka, and more.This is Part 1, covering 1973–2003: a journey of grit, sandals, lawsuits, and ugly boots that somehow took over the world.Join the Skippy and Doogles fan club. You can also get more details about the show at skippydoogles.com, show notes on our Substack, and send comments or questions to skippydoogles@gmail.com.

In this engaging conversation, Tommie Runz discusses the evolution of Teva as a brand in the outdoor footwear industry, highlighting its commitment to innovation and athlete feedback. The discussion features insights from ultra runner Mike Wardian and Henry, Teva's design head, focusing on the unique challenges and experiences of trail running. The conversation also touches on personal stories, the importance of community in outdoor activities, and the spirit of adventure that drives both the athletes and the brand.

Recorded live at the SAP for Treasury and Working Capital Management Conference in Rome, Eleanor Hill (TMI) sat down with Mickey Ben Moshe (Teva Global Treasury) to discuss Teva's global transformation and the wider working capital and supply chain landscape. Mickey reflects on Teva's shift to a cash-sensitive organisation, highlighting how treasury played a key role in reshaping the company's financial culture. He also explores treasury's influence in driving operational excellence, the rising importance of working capital on the CFO agenda, and how SCF tools are helping to unlock liquidity.

Dust off that box in your attic that has your Teva sandals, Abercrombie visor and puka shell necklaces, because we are heading back to the Beach! We are continuing in our Leo-Mini-series covering his career and films from the late 90s to mid-2000s. During this time, Leo's “Posse” was ruling the sunset strip while Leo's films stayed firmly in the past. Is 2002 one of the best years in film? Like Frank Abagnale asked, “Do you concur?”

ITPM Flash provides insight into what professional traders are thinking about in the markets RIGHT NOW! In this episode, Raj Malhotra explains why the recent rally in the S&P 500 could still have legs, potentially reaching 7100+ by next May if history repeats. But the key, he argues, is breadth: a broad-based rally across sectors, not just large-cap tech. Raj highlights the RSP equal-weight ETF as the signal to watch and spotlights Deckers Outdoor (DECK)—parent of HOKA, UGG, and Teva—as a beaten-down small/mid-cap with strong fundamentals, margin expansion, and international growth. He outlines a calendar spread trade with asymmetric upside if DECK rallies as the market broadens.

Teva Pharmaceutical Industries reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy. CEO Richard Francis speaks with Bloomberg's Scarlet Fu and Katie Griefeld. See omnystudio.com/listener for privacy information.

Former NEC Director and former Goldman Sachs President Gary Cohn reacts to this morning's GDP print and the President's continued call for the Fed to lower rates. Plus an exclusive with the CEO of Oreo maker Mondelez, raising prices to offset an “unprecedented” rise in cocoa prices. Then the CEO of Teva Pharma breaks down the impact of tariffs for the Israeli based company, after narrowing its full-year outlook. And Finally what results from Meta and Amazon could signal about the AI opportunity in the ad market.

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 11, 2025. In this episode: Merck & Co's Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee's Phase II eczema win; and a look at India's wave of licensing. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-TJX4YBGD5JDSHGRUTLYHWO2JMU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company through nine consecutive quarters of growth. On this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits down with Francis to talk about the progress made so far on Teva’s “Pivot to Growth” strategy and what comes next. They dig into the strategies behind the company’s chief commercial medicines, its pipeline darlings and the way Teva’s generic and biosimilar backbone is expected to evolve through the end of the decade. To learn more about the topics in this episode: As Austedo, Ajovy and Uzedy gain steam, Teva banks on $5B-plus in 2030 innovative drug sales Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase Teva taps Matthew Shields to oversee manufacturing and supply division amid company revamp This week's episode is sponsored by Cencora. See omnystudio.com/listener for privacy information.

In this episode I sit down with Mike Denzer, a mechanical engineer, inventor, and trusted leader in the combination product space. We talk about the power of networking not just as a tool for finding your next job, but as a foundation for building a meaningful and resilient career in pharma and medtech.Mike shares what it's like to develop life-changing devices like Amgen's Auto Click autoinjector, how he built credibility across R&D and regulatory teams, and why asking good questions and being generous with your time pays off more than any formal title. If you've ever struggled to balance technical depth with approachability or you're trying to navigate CROs, design controls, or cross-functional chaos, I hope you enjoy this conversation! ⏱️ Timestamps00:00 Welcome and introduction00:56 Why networking matters01:57 Life-changing moments in engineering09:45 Challenges and innovations in autoinjectors14:47 CROs, sponsors, and collaboration18:22 Mike's favorite projects and final thoughtsAbout Mike Denzer:Mike Denzer is a mechanical engineer, inventor, and combination product leader with over 20 years of experience in drug delivery system development. He's held leadership roles at companies like Amgen, Teva, Bristol Myers Squibb, and Kymanox, and is credited as an inventor on five U.S. patents related to autoinjector platforms and delivery technology.He's the founder of Combo Products LLC, where he now consults on combination product design, human factors strategy, and technical development. Mike is widely respected for his collaborative style and clear communication across engineering, clinical, regulatory, and quality functions.Contact Mike: mdenzer@comboproductsllc.comSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations, and R&D, he has worked in large Medical Device and Pharma organizations to support the development and launch of hardware devices, disposable devices, and combination products for vaccines, generics, and biologics.Subhi currently serves as the International Committee Chair for the Combination Products Coalition (CPC), is a member of ASTM Committee E55, and has served on AAMI's Combination Products Committee.

De tant en tant, tot enregistrant una can

In this CME podcast episode, Dr. Andrew Cutler interviews Dr. Phillip Coffin, Director of the Center on Substance Use and Health in San Francisco, CA, about the management of stimulant use disorders. They explore the challenges of treatment and highlight the importance of harm reduction strategies to enhance patients' quality of life.  CME credit is available to NEI Members only.   Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Summarize pharmacologic and behavioral treatment strategies for stimulant use disorders, particularly methamphetamine and cocaine Evaluate the evidence base for current and investigational medications used in clinical trials and real-world settings Apply harm reduction principles and integrated care models to improve outcomes for patients with stimulant use disorders in diverse clinical settings Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: June 18, 2025*   Expiration: June 17, 2028 *NEI and HMP Education maintain a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-02.  Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until June 17, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD, LFAPA specializing in psychiatry, forensic, addiction to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Phillip Coffin, MD, MIA Director of Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA No financial relationships to disclose. The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, Stephen Daniels and Bahgwan Bahroo, MD, LFAPA. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Elle n'a pas sa langue dans sa poche pour tirer à gros boulets sur l'idée et les clichés de la "bonne mère", et pourtant, à quelques jours de son premier accouchement, l'humoriste Laura Domenge nous a confié ses préoccupations et sa façon de se préparer à devenir mère : déconnecter, bricoler, cuisiner, envoyer son mec aux séances de prépa accouchement sans elle, éviter l'actu anxiogène avec des séries feel good... On a beaucoup ri avec elle et partagé ses idées sur l'accouchement et l'arrivée d'un bébé dans une vie de femme.(Re)découvrez l'un de vos épisodes préférés avec Laura Domenge, humoriste comédienne et autrice, chroniqueuse sur France Inter et sur Teva.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Christiane Bardroff, COO of Rentschler Biopharma SE. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Christiane, covering: The importance of "knowing what you're talking about" to build confidence Being asked to build and commission an automated €800m bioprocessing plant at Teva The draw of a family-owned CDMO business servicing 170 clients worldwide, and what she loves about this ownership model The 'power of we' is doing things together as a team for the greater good of the business The power of listening to people and empowering teams that led to producing 50% more at the same site Why Rentschler Biopharma decided to exit the CGT capabilities and double down on its biologics business Christiane oversees operations across the company's sites in Germany and the US. A results-driven executive with a strong foundation in biotechnology and chemical engineering, she brings deep expertise across biomanufacturing, automation, digitalization, and leadership. Her career includes nearly a decade at Roche, where she implemented the company's first paperless manufacturing process. At Teva Biotech, she led the development of a €800M large-scale facility and was part of the global management team, earning Teva's Mission and Values Award in 2021. Since joining Rentschler in 2022, Christiane has advanced rapidly through senior leadership roles and now leads all operational areas, including manufacturing, quality, engineering, regulatory, and supply chain. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Send us a textIn this episode, we dive deeper into the imperfect tense by talking about what our school routines used to be like. You'll review common daily routine verbs, learn time expressions, and build longer sentences in context. Through storytelling, guided practice, and a short dialogue, you'll get comfortable using the imperfect tense to describe past habits. Great for intermediate learners looking to make their Catalan more natural and fluid!The current group classes are going so well that I would love to do more in September, so I am just trying to get an idea of interest and available dates/times for everyone. Please fill in a short survey if you would be interested in classes:https://www.thelazylinguist.co.uk/group-programmesLicensed to Explore with RohitWelcome to Licensed to Explore with Rohit — a...Listen on: Apple Podcasts SpotifySupport the showGroup Lessons starting September 2025: Group ProgrammesBeginners Course: Catalan for Beginners CoursePatreon: The Lazy Linguist Buy us a coffee: Buy me a Coffee Instagram: @lazylinguistcatalan Facebook: The Lazy Linguist PodcastChristina offers private lessons - enquire through a DM on socials or through the link: Private lessons

If you're looking for a podcast episode that moves beyond surface-level talk and gets into the heart of why environmental justice matters, this episode of The Unfolding: Presented by The Loveland Foundation Podcast is worth your time.Host Rachel Keener sits down with Leah Thomas — known to many as Green Girl — an environmental activist and the voice behind the term intersectional environmentalist. Leah opens up about her path from growing up in Missouri to becoming a leading voice in the sustainability space, tracing how something as personal as her natural hair journey first got her thinking about what sustainability really means.But this isn't just about recycling or climate stats. Leah draws powerful connections between environmental issues and social and racial justice, explaining why true sustainability has to include communities that have long been left out of the conversation — especially Black communities. She shares how she builds spaces of care and creativity, like her Crafting Club, where people can come together, learn to make everyday items, and support one another.This episode doesn't fall into the trap of focusing only on crisis and catastrophe. Instead, Leah talks about the joy and healing that can come from reconnecting with the earth, caring for our mental health, and building community-based solutions. It's a conversation that offers hope without ignoring hard truths — and a reminder that the future can look different if we all understand and honor our connection to the planet.If you want to feel inspired and grounded at the same time, give this episode a listen.More about Leah Thomas @GreenGirlLeah:Leah is a celebrated environmentalist based in Los Angeles, CA. Coining the term ‘eco-communicator' to describe her style of environmental activism. Leah uses her passion for writing and creativity to explore and advocate for the critical yet often overlooked relationship between social justice and environmentalism. Her work includes consulting with brands like Apple and TAZO, projects with Meta, KEEN, TEVA, Indie Best Selling Book The Intersectional Environmentalist, and working on the Communications team at Patagonia HQ. Learn more about Leah Thomas HERE.–The Unfolding: Presented by The Loveland Foundation podcast is an additional resource not only to the public but also to our therapy fund cohort members. The Loveland Foundation therapy fund and resources are only made possible through support from our community. At The Loveland Foundation, we are committed to showing up for communities of color in unique and powerful ways, with a particular focus on Black women and girls. Our resources and initiatives are collaborative and they prioritize opportunity, access, validation, and healing. Since our founding, the Therapy Fund has provided financial support for therapy to over 13,000 Black women, girls, and non-binary individuals across the country.Links:Donate to Camp Loveland: https://thelovelandfoundation.org/donateSupport the show: https://give.thelovelandfoundation.org/give/436656/#!/donation/checkoutFollow Leah on Instagram: https://www.instagram.com/greengirlleah/Follow The Loveland Foundation on Instagram: https://www.instagram.com/thelovelandfoundation/Visit the website: https://thelovelandfoundation.org/Support the show

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.  Uncover: ·      The importance of patient phenotyping: How can biomarkers and imaging improve asthma management? ·      Mucus plugging and airflow obstruction: What does the latest research reveal? ·      Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling? ·      The role of imaging in clinical practice: How can CT scans provide new insights into asthma care? Speakers Mario Castro, University of Kansas School of Medicine, United States Njira Lugogo, University of Michigan, Ann Arbor, Michigan, United States Disclaimers: ·      This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ·      The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program ·      The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits ·      See full US Prescribing Information for dupilumab ·      MAT-US-2412937 v2.0 - Pro1 Expiration Date: 04/21/2026 Speaker disclosures: ·      MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics. ·      NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK. References: 1.        Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.

Is the rally overdone? HSBC says yes. We'll speak to the company's chief of multi-asset strategy. Plus, the pharma is facing lots of headwinds on several fronts. We'll speak with the CEO of Teva about how the industry can respond and get through it. And, an interview with the Education Secretary, Linda McMahon about the administration's battle with Harvard.

Three guests on this super-sized episode! Senior OLB Tevarua Tafiti takes us inside the locker room as Stanford spring football continues. Stanford Men's Gymnastics Head Coach Thom Glielmi previews this week's NCAA Championships as the Cardinal aim for its sixth straight national title. And Associate Athletic Director, Facilities & Housing Dan Levine tells how Stanford Stadium became a softball facility this season and what it took to get ready for this week's Big Swing!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textJoin us for this episode as we dive a little deeper into the Imperfect Tense in Catalan. We use this tense to talk about recurring actions in the past or to describe things in the past.Tune in to find out more and specifically how to talk about what our school days were like!Let us know how you found the episode/how you are finding the Pod in general or anything else. We love getting to know our listeners!Support the showGroup Lessons starting 7th April 2025: Group ProgrammesBeginners Course: Catalan for Beginners CoursePatreon: The Lazy Linguist Buy us a coffee: Buy me a Coffee Instagram: @lazylinguistcatalan Facebook: The Lazy Linguist PodcastChristina offers private lessons - enquire through a DM on socials or through the link: Private lessons